FGD3 and cancer: Given the obvious cohort differences in treatment conditions, patient populations, formalin-fixed paraffin-embedded frozen tissue, and platform differences in Illumina and RNA-seq, FGD3 represents a robust indicator of outcome in breast cancer as well as other cancers and requires further study.